Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Rationale Lisdexamfetamine is a prodrug of D-amphetamine used for the treatment of attention-deficit/hyperactivity disorder (ADHD). Lisdexamfetamine is thought to have a prolonged pharmacokinetic profile compared with oral D-amphetamine, possibly associated with lower drug liking and a lower risk of oral misuse. However, differences in the pharmacokinetics and pharmacodynamics of lisdexamfetamine and D-amphetamine have not been directly compared. Methods Equimolar doses of D-amphetamine (40mg) and lisdexamfetamine (100mg), and placebo were administered in 24 healthy subjects in a randomized, double-blind, placebo-controlled, cross-over study. Plasma concentrations of amphetamine, subjective effects, and vital signs were repeatedly assessed. The pharmacokinetic parameters were determined using compartmental modeling. Results The increase in plasma concentrations of amphetamine had a 0.6±0.6 h (mean±SD) longer lag time and reached peak levels 1.1±1.5 h later after lisdexamfetamine administration compared with D-amphetamine administration, but no differences in maximal concentrations or total exposure (AUC) were found between the two treatments. Consistent with the pharmacokinetics, the subjective and cardiovascular stimulant effects of lisdexamfetamine also occurred later compared with D-amphetamine. However, no differences in peak ratings of potentially abuse-related subjective drug effects (e.g., drug liking, drug high, stimulation, happy, well-being, and self-confidence) were observed after lisdexamfetamine administration compared with D-amphetamine administration. Lisdexamfetamine and D-amphetamine also produced similar peak increases in mean arterial blood pressure, heart rate, body temperature, pupil size, and adverse effects. Conclusions The pharmacokinetics and pharmacodynamics of lisdexamfetamine are similar to D-amphetamine administered 1h later. Lisdexamfetamine is likely associated with a similar risk of oral abuse as D-amphetamine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis
Faraone, S. V., & Buitelaar, J. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0054-3 · Cited by 485
Variables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD
Volkow, N. D., & Swanson, J. M. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.11.1909 · Cited by 475 · cited 2×
“Substances with a slow absorption rate are less likely to be abused than drugs with a rapid absorption rate (Busto and Sellers, 1986; Farre and Cami, 1991; Volkow and Swanson, 2003).”
BackgroundDifferential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase
White, T. L., Justice, A. J. H., & de Wit, H. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00818-3 · Cited by 248 · cited 1×
“Female subjects were investigated during the follicular phase of their menstrual cycle (days 2–14) to account for cyclic changes in the reactivity to D-amphetamine (White et al., 2002).”
BackgroundAbsorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine
Pennick (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s9749 · Cited by 170 · cited 2×
“Inactive lisdexamfetamine is completely (>98%) converted to its active metabolite D-amphetamine in the circulation (Pennick, 2010; Sharman and Pennick, 2014).”
BackgroundDifferential effects of MDMA and methylphenidate on social cognition
Schmid, Y., Hysek, C. M., Simmler, L. D., Crockett, M. J., Quednow, B. B., & Liechti, M. E. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114542454 · Cited by 155 · cited 1×
“…“any drug effect,” “good drug effect,” “bad drug effect,” “drug liking,” “drug high,” “stimulated,” “alertness,” “content,” “happy,” “closeness to others,” “talkative,” “open,” “concentration,” “trust,” and “want to be with others” and have previously been used (Schmid et al., 2014, 2015b).”
Self-citationJasinski, D., & Krishnan, S. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109103113 · Cited by 149 · cited 16×
“Nonetheless, this previous study (Jasinski and Krishnan, 2009a) did not assess the pharmacokinetics of amphetamine to demonstrate the equivalence of the doses used.”
BackgroundResultInfluentialFindling, R. L., Childress, A. C., Cutler, A. J., Gasior, M., Hamdani, M., Ferreira-Cornwell, M. C., & Squires, L. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.01.007 · Cited by 120
Jasinski, D., & Krishnan, S. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108093841 · Cited by 100
Plasma levels of d-amphetamine in hyperactive children: Serial behavior and motor responses
Brown, G. L., Hunt, R. D., Ebert, M. H., Bunney, W. E., & Kopin, I. J. (1979) · Psychopharmacology · doi:10.1007/bf00427126 · Cited by 97 · cited 1×
“The present pharmacokinetic data for lisdexamfetamine and D-amphetamine are consistent with previous investigations of either formulation alone (Brown et al., 1979; Brauer et al., 1996; Krishnan et al., 2008; Ermer et al., 2010; Steer et al., 2012; Comiran et al., 2016; Adler et al., 2017).”
ResultA Systematic Review of the Safety of Lisdexamfetamine Dimesylate
Coghill, D. R., Caballero, B., Sorooshian, S., & Civil, R. (2014) · CNS Drugs · doi:10.1007/s40263-014-0166-2 · Cited by 89 · cited 1×
“Such a prolonged pharmacokinetic profile is considered to be associated with slower effects on dopamine release, lower euphoric effects, and a possibly lower risk of misuse (Jasinski and Krishnan, 2009a; Heal et al., 2013; Coghill et al., 2014).”
Background
Research works printed but not linked: 27
- Adler, Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder., Behav. Brain Funct., 5, 10.1186/1744-9081-5-34 · DOI · Paper page
- Angrist, 1987, Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects., Biol. Psychiatry, 22, 1357, 10.1016/0006-3223(87)90070-9 · DOI · Paper page
- Banks, 2015, Preclinical assessment of lisdexamfetamine as an agonist medication candidate for cocaine addiction: effects in rhesus monkeys trained to discriminate cocaine or to self-administer cocaine in a cocaine versus food choice procedure., Int. J. Neuropsychopharmacol., 18, 10.1093/ijnp/pyv009 · DOI · Paper page
- Brauer, 1996, Acute tolerance to subjective but not cardiovascular effects of d-amphetamine in normal, healthy men., J. Clin. Psychopharmacol., 16, 72, 10.1097/00004714-199602000-00012 · DOI · Paper page
- Busto, 1986, Pharmacokinetic determinants of drug abuse and dependence. A conceptual perspective., Clin. Pharmacokinet., 11, 144, 10.2165/00003088-198611020-00004 · DOI
- Clausen, 2005, Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults., CNS Spectr., 10, 6, 10.1017/S109285290000239X · DOI · Paper page
- 2016, European Drug Report 2016.
- Farre, 1991, Pharmacokinetic considerations in abuse liability evaluation., Br. J. Addict., 86, 1601, 10.1111/j.1360-0443.1991.tb01754.x · DOI · Paper page
- Haffey, 2009, Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults., Postgrad. Med., 121, 11, 10.3810/pgm.2009.09.2048 · DOI · Paper page
- Heal, 2013, Amphetamine, past and present–a pharmacological and clinical perspective., J. Psychopharmacol., 27, 479, 10.1177/0269881113482532 · DOI · Paper page
- Hysek, 2012, Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex., Psychopharmacology, 224, 363, 10.1007/s00213-012-2761-6 · DOI
- Hysek, 2012, Duloxetine inhibits effects of MDMA (”ecstasy”) in vitro and in humans in a randomized placebo-controlled laboratory study., PLoS ONE, 7, 10.1371/journal.pone.0036476 · DOI · Paper page
- Hysek, 2014, Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone and in combination., Int. J. Neuropsychopharmacol., 17, 371, 10.1017/S1461145713001132 · DOI · Paper page
- Janke, 1978, Die Eigenschaftswörterliste.
- Johnston, 2016, Monitoring the Future: National Survey Results on Drug Use, 1975-2015: College Students and Adults Ages 19-55
- Kaland, 2015, Comparison of lisdexamfetamine and dextroamphetamine exposures reported to U.S. poison centers., Clin. Toxicol., 53, 477, 10.3109/15563650.2015.1027903 · DOI · Paper page
- Kirkpatrick, 2012, Acute and residual interactive effects of repeated administrations of oral methamphetamine and alcohol in humans., Psychopharmacology, 219, 191, 10.1007/s00213-011-2390-5 · DOI
- Krishnan, 2008, Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers., Clin. Drug Investig., 28, 745, 10.2165/0044011-200828120-00002 · DOI
- Lile, 2011, Comparison of the behavioral and cardiovascular effects of intranasal and oral d-amphetamine in healthy human subjects., J. Clin. Pharmacol., 51, 888, 10.1177/0091270010375956 · DOI
- Parasrampuria, 2007, Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users., J. Clin. Psychopharmacol., 27, 459, 10.1097/jcp.0b013e3181515205 · DOI · Paper page
- Rosen, 1965, Absorption and excretion of radioactively tagged dextroamphetamine sulfate from a sustained-release preparation., JAMA, 194, 1203, 10.1001/jama.1965.03090240037010 · doi:10.1001/jama.1965.03090240037010
- Schmid, Acute effects of lysergic acid diethylamide in healthy subjects., Biol. Psychiatry, 78, 544, 10.1016/j.biopsych.2014.11.015 · DOI · Paper page
- Schmid, Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects., J. Pharmacol. Exp. Ther., 353, 102, 10.1124/jpet.114.222356 · DOI
- Simmler, 2013, Pharmacological characterization of designer cathinones in vitro., Br. J. Pharmacol., 168, 458, 10.1111/j.1476-5381.2012.02145.x · DOI · Paper page
- Simmler, 2014, Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives., Biochem. Pharmacol., 88, 237, 10.1016/j.bcp.2014.01.024 · DOI
- Smith, 2016, Individual differences in timing of peak positive subjective responses to d-amphetamine: relationship to pharmacokinetics and physiology., J. Psychopharmacol., 30, 330, 10.1177/0269881116631650 · DOI
- Zerssen, 1976, Die Beschwerden-Liste.
Cited by
Designer drugs: mechanism of action and adverse effects
Luethi, D., & Liechti, M. E. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02693-7 · Cited by 262
Self-citationDistinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
Holze, F., Vizeli, P., Müller, F., Ley, L., Duerig, R., Varghese, N., Eckert, A., Borgwardt, S., & Liechti, M. E. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0569-3 · Cited by 247
Self-citationDolder, P. C., Strajhar, P., Vizeli, P., Odermatt, A., & Liechti, M. E. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4849-0 · Cited by 34
Self-citationWard, K., & Citrome, L. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1420163 · Cited by 32
“delayed time to maximum concentration of d-amphetamine with LDX, but similar d-amphetamine AUC), Visual Analog Scale measures of abuse liability (drug liking, well-being, and more) were not different between d-amphetamine and LDX when compared to placebo [62].”
BackgroundStrajhar, P., Vizeli, P., Patt, M., Dolder, P. C., Kratschmar, D. V., Liechti, M. E., & Odermatt, A. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2018.10.016 · Cited by 17
“Subjective, autonomic, and 219 adverse responses were also assessed and have been reported in detail elsewhere [11].”
InfluentialSelf-citation
Metadata
- Authors
- Dolder, P. C., Strajhar, P., Vizeli, P., Hammann, F., Odermatt, A., & Liechti, M. E.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2017-09-07
- Volume
- 8
- Pages
- 617-617
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2750699103
- Cited by
- 57
- References
- 24
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030_170249)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects. https://app.cochat.ai/papers/10.3389/fphar.2017.00617
- The paper
- Dolder, P. C., Strajhar, P., Vizeli, P., Hammann, F., Odermatt, A., & Liechti, M. E. (2017). Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2017.00617
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.